



July 1, 2002

2900 '02 JUL -9 10:07

Rhode Island Chapter

Chapter President

Richard Smith, MD, FAAP
Woonsocket Junior Health Center
206 Cass Avenue
Woonsocket, RI 02895
401/769-1234
Fax: 401/769-8076
E-mail: woody12782@pol.net

Chapter Vice President

Carole Jenny, MD, MBA, FAAP
Hasbro Children's Hospital
Child Protection Program
595 Eddy Street
Providence, RI 02903
401/444-3996
Fax: 401/444-7397
E-mail: cjenny@Lifespan.org

Chapter Secretary-Treasurer

Keivan Ettefagh, MD, FAAP
Aquidneck Medical Associates
Memorial Boulevard
Newport, RI 02840
401/847-2290 ext 237
Fax: 401/849-8446
E-mail: ettefaghke@prodigy.net

Chapter Executive Board

Robert Burke, MD, FAAP
David Chronley, MD, FAAP
(Ex-Officio)
Richard Dvorin, MD, FAAP
(Ex-Officio)
John E Farley, MD, FAAP
(Ex-Officio)
Mary Margaret Gleason, MD
Ellen Gurney, MD, FAAP
William H Hollinshead, MD, FAAP
Alessandra Kazura, MD, FAAP
Lisa Keswick, MD, FAAP
Louise S Kiessling, MD, FAAP
Elizabeth B Lange, MD, FAAP
Victor Lerish, MD, FAAP
(Ex-Officio)
Edward D McGookin, MD, FAAP
William Oh, MD, FAAP
George Peter, MD, FAAP
Fortunato Procopio, MD, FAAP
Monica J Schaberg, MD, MPH, FAAP
(Ex-Officio)
Peter Simon, MD, MPH, FAAP
(Ex-Officio)
Andrew M Snyder, MD, FAAP
Dale Steele, MD, FAAP
Thomas F Tracy Jr, MD, FAAP
Rosalind Vaz, MD, FAAP
(Ex-Officio)
Patrick M Vivier, MD, PhD, FAAP
Judith Westrick, MD, FAAP

Recording Secretary

Anne L McKinnon, MS, RN

Chapter Executive Director

Laurey Collins Burris
877/227-7447
E-mail: lburris@bellatlantic.net

**Dockets Management Branch
(HFA-305)**

Food and Drug Administration
5630 Fishers Lane - Room 1061
Rockville, MD 20652
<http://www.fda.gov/dockets/ecomments>
Docket Number: 02N-0152

Dear Sir or Madam:

As a pediatrician who cares for infants and children every day, I welcome the opportunity to comment on the relationship between the 1998 Pediatric Rule and the Best Pharmaceuticals for Children Act (P.L. 107-109). As a member of the American Academy of Pediatrics (AAP), I know that the AAP has advocated for appropriately tested and labeled medications for infants, children and adolescents for over 40 years. Securing safe and appropriate drugs for use by children has had a long and laborious history. Significant progress toward pediatric drug studies and labeling has been made over the last five years. A dual approach to obtaining essential pediatric data was instituted in the late 1990's. This approach combines: 1) incentives for voluntary studies of drug safety and dosing by industry (extended in January 2002 in the Best Pharmaceuticals for Children Act [BPCA]); and 2) a regulation requiring pediatric studies of new drugs and some already marketed drugs, known as the Pediatric Rule.

In March 2002 the FDA proposed to suspend the Pediatric Rule. While this proposal was reversed, this action indicates that children are at risk of losing the ground we have fought so hard to secure for them.

The Pediatric Rule ensures that children are no longer a therapeutic afterthought by the pharmaceutical industry. It is an essential and successful tool in ensuring that children have the quality and quantity of drugs they need. All new drugs must be studied for pediatric use at the time a drug comes to market unless the FDA grants a waiver. This makes medications for children a certainty, not an option and puts children on a level playing field with adults for the first time. I believe that all components of the 1998 Pediatric Rule must be preserved. It is a comprehensive approach to securing pediatric studies. FDA has not yet invoked all the provisions of the Pediatric Rule; however, together they weave a safety net for children to ensure that children have appropriate drugs available for their use.

The following comments and recommendations respond to questions and issues raised in the Federal Register notice soliciting public comments:

- Retiring or relaxing any authorities currently in the Pediatric Rule is inappropriate and would be to the detriment of children. It must always be kept in mind that BPCA is time-limited, voluntary and subject to continuation by the Congress. Those facts speak directly to the need to ensure that the Pediatric Rule remains in place in its entirety.
- Noting again that the BPCA is subject to continuation by Congress and that future reauthorization is uncertain, the Pediatric Rule should mirror the scope of the BPCA and apply to all labeled and potential indications as well as new indications. If a company submits a supplemental indication to the FDA, it invokes the Pediatric Rule. It is important that appropriate pediatric studies be conducted for that new use; and if the current label lacks appropriate pediatric use information (e.g., for neonates) the FDA should also include in their

02N-0152

C 67

American Academy
of Pediatrics



DÉDICATED TO THE HEALTH OF ALL CHILDREN™

Rhode Island Chapter



Dockets Management Branch
(HFA-305)
Food and Drug Administration
5630 Fishers Lane - Room 1061
Rockville, MD 20652

20857+0001

